Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Labopharm completes US$113.7 million cross-border public offering

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Labopharm Inc.

On May 3, 2006, Labopharm inc., an international specialty pharmaceutical company focused on improving existing drugs incorporating Contramid, the company's proprietary advanced controlled-release technology, completed a public offering of 12,650,000 common shares at a price of $8.99 per share for total estimated gross proceeds to the company of $113.7 million. The offering, which was made in Canada and in the United States under the Multijurisdictional Disclosure System, was Labopharm's initial public offering in the US. The company's common shares are now listed on the TSX and on NASDAQ. Labopharm was represented in-house by Lynda Covello, general counsel and corporate secretary, and in Canada by Fasken Martineau with a team that included Louis-François Hogue, Frédéric Boucher, Marie-Josée Vincelli, Alexis Steinman, Lucie Dufour (IP) and Gilles Carli (tax) as well as Julie Gauvreau (IP) of affiliate firm Goudreau Gage Dubuc.

    Subscribe

    Receive email updates from our team

    Subscribe